M1 receptor antagonists(Muscarinic acetylcholine receptor M1 antagonists), M3 receptor antagonists(Muscarinic acetylcholine receptor M3 antagonists), Radiography enhancers

Therapeutic Areas

Nervous System DiseasesCardiovascular DiseasesSkin and Musculoskeletal Diseases+ [2]

Active Indication

Breast DiseasesAortic DiseasesCardiovascular Diseases+ [5]

Inactive Indication-

Originator Organization-

Active Organization

Bayer HealthCare Pharmaceuticals, Inc.Bayer Healthcare LLCBayer Australia Ltd.

+ [2]

Inactive Organization

Bayer AGBayer, Inc.

License Organization

Jiangsu Wuzhong Medicine Group Co., Ltd.

Suzhou Tianmayiyao Group Tianji Biology Pharmacy Co. Ltd.

Drug Highest PhaseApproved

First Approval Date

Australia (12 Sep 1991),

Contrast agents

Regulation-

Structure/Sequence

Molecular FormulaC18H24I3N3O8

InChIKeyDGAIEPBNLOQYER-UHFFFAOYSA-N

CAS Registry73334-07-3

Clinical Trials associated with Iopromide

NCT07391787

/ CompletedNot ApplicableIIT

Low-acid Contrast Media for Preventing Post ERCP Pancreatitis: a Multicenter, Retrospective, Cohort Study

Title： Low-acid contrast media for preventing post ERCP pancreatitis: a multicenter, retrospective, cohort study (LAMP-R) .
Objective:
Main objective: This study aims to determine whether low-acid contrast media can reduce the incidence of post-ERCP pancreatitis.
Secondary objective: To investigate the severity of post-ERCP pancreatitis, the incidence rate of other complications, and the risk factors associated with different pH values of contrast media.
Research Design：Multicenter, retrospective cohort study.
Research participants:
Inclusion criteria: Patients aged 18 to 90 years who underwent ERCP diagnostic and therapeutic procedures were included consecutively.
Exclusion criteria: Patients who did not use contrast medium during ERCP, failed ERCP papillary intubation, developed acute pancreatitis within 3 days before surgery, ERCP stent removal/replacement, had a history of pancreaticoduodenectomy or biliary-enteric anastomosis, and whose postoperative amylase/lipase levels could not be traced were excluded.
Outcomes:
1. The rate of post-ERCP pancreatitis and severity of PEP 2. The rate of infection 3. The rate of gastrointestinal bleeding 4. The rate of perforation.
Sample size calculation:
A total of approximately 3,881 eligible ERCP patients were included from five tertiary Grade A centers. Specifically, 2,305 patients were from Qilu Hospital of Shandong University, 463 from Linyi People's Hospital, 121 from Qilu Third Hospital of Shandong University, 106 from Dezhou Hospital of Qilu Hospital of Shandong University, and 886 from Shengli Oilfield Central Hospital.
Statistical analysis SPSS 27 is used for statistics and analysis, including descriptive analysis, single-factor and multi-factor logistic regression analysis, analysis of variance, t-test, propensity score matching (PSM), etc. Categorical data are presented as counts and proportions, while continuous data are presented as mean ± standard deviation, depending on the distribution. Categorical data are analyzed using χ2 and Fisher's exact test, and continuous data are analyzed using Student's t-test or Mann-Whitney U test. Primary and secondary outcomes are presented as relative risks (RRs) with 95% confidence intervals (CIs).

Start Date01 Aug 2025

Sponsor / Collaborator

Shandong University

JPRN-jRCTs041230098

/ RecruitingNot Applicable

Utility of High-Concentration Contrast Material for Dual-Energy CT Angiography

Start Date27 Oct 2023

Sponsor / Collaborator-

NCT03631771

/ WithdrawnPhase 4

A Multicenter, Prospective Study to Evaluate the Risk of Hypothyroidism in Pediatric Patients Administered Intravascular Iohexol, Iodixanol, Iopromide, or Ioversol. THYROPED.

This is a Phase 4 multicenter prospective study to estimate the proportion of patients aged birth to 3 years who develop hypothyroidism within 6 months after receiving intravascular iohexol (Omnipaque™), iodixanol (Visipaque™), iopromide (Ultravist®), or ioversol (Optiray®) as the iodinated contrast medium (ICM) for clinical evaluation during an ICM-enhanced diagnostic imaging procedure.

Start Date01 Mar 2022

Sponsor / Collaborator

GE Healthcare Holdings, Inc.

[+2]

100 Clinical Results associated with Iopromide

100 Translational Medicine associated with Iopromide

100 Patents (Medical) associated with Iopromide

1,225

Literatures (Medical) associated with Iopromide

01 Jul 2026·JAVMA-JOURNAL OF THE AMERICAN VETERINARY MEDICAL ASSOCIATION

Intravenous iodinated contrast media transiently increases urine specific gravity and pH without affecting other urinalysis parameters after computed tomography examination in dogs

Article

Author: Rannou, Benoit ; Edery, Elsa ; Dor, Cécile ; Fritz, Julien ; Barthe, Swann ; Rault, Delphine

Abstract:

Objective:

To evaluate the immediate influence of iopromide, a nonionic iodinated contrast medium for IV use, on urinalysis in dogs undergoing CT scanning, including urine specific gravity (USG), urine dipstick parameters, urinary sediment, and urinary protein-to-creatinine ratio (UPCR).

Methods:

This prospective, 1-group pretest, post-test experimental study included 30 client-owned dogs undergoing CT between May 1 and July 31, 2024. Cystocentesis samples were collected immediately before and within 30 minutes after IV iodinated contrast medium (IVIC) administration and analyzed by the same laboratory.

Results:

Following IVIC administration, median USG increased significantly from 1.046 (95% CI, 1.032 to 1.052) to 1.058 (95% CI, 1.044 to 1.068) and median urine pH increased significantly from 6.25 (range, 5 to 9) to 7 (range, 5 to 9). No significant changes were observed in other urine dipstick parameters, urinary sediment, or UPCR after IVIC administration.

Conclusions:

Our study suggests that IV iopromide transiently alters USG and pH in dogs, whereas other urinalysis parameters remain unaffected. Clinicians can rely on most urinalysis parameters, particularly proteinuria and sediment, to guide immediate clinical decisions.

Clinical Relevance:

These findings provide practical guidance for accurate interpretation of urinalysis in dogs undergoing CT with contrast media. If USG or pH are critical for patient management, urinalysis should be performed before or on a different day than contrast administration.

30 Jun 2026·ENVIRONMENTAL SCIENCE & TECHNOLOGY

Fate of Trace Organic Contaminants in the Hyporheic Zone: A Laboratory-Scale Column Experiment

Article

Author: Lutze, Holger V. ; Ihle, Kai ; Hillmann, Selina ; Bertold, Carolin ; Schulz, Stephan ; Schüth, Christoph ; Muñoz-Vega, Edinsson ; Abdighahroudi, Mohammad Sajjad

Rivers impacted by anthropogenic activities often contain numerous trace organic contaminants (TrOCs) that can infiltrate aquifers. The hyporheic zone, which is the interface between rivers and groundwater, can act as a natural attenuation barrier via sorption and biotransformation. To differentiate between these two processes, we conducted long-term laboratory column experiments using riverbed sediments from a creek downstream of wastewater treatment plants to quantify the fate of several ubiquitous TrOCs with diverse physicochemical properties. Triplicate columns were fed with either natural contaminated river water or with TrOC-free tap water to distinguish between attenuation mechanisms and to investigate potential remobilization. Mass balances and comparisons between experiments revealed a variety of attenuation behaviors. Certain hydrophobic (e.g., carbamazepine and tolyltriazole) or cationic compounds (e.g., metoprolol and sitagliptin) were retained by sediment sorption, whereas several polar anionic TrOCs remained largely mobile (e.g., hydrochlorothiazide and gabapentin), with some of them being biotransformed under prevalent reducing conditions (e.g., iopromide and oxipurinol). Overall, 10 out of 19 continuously detected TrOCs exhibited less than 25% removal over almost 300 pore volumes, reflecting limited biotransformation and the relevance of reversible sorption. These results suggest that while polluted hyporheic sediments of high organic matter content can temporarily reduce contaminant transport, their attenuation capacity is limited. Furthermore, previously sorbed pollutants may remobilize, posing long-term risks to the groundwater quality.

01 Jun 2026·INTERNATIONAL JOURNAL OF DERMATOLOGY

Iodinated Contrast–Induced AGEP and ALEP : Recognition, Diagnosis, and Management

Review

Author: Pejcic, Ana V. ; Tardioli, Mariana Okabe

ABSTRACT:

Acute generalized exanthematous pustulosis (AGEP) and acute localized exanthematous pustulosis (ALEP) are rare T‐cell‐mediated hypersensitivity reactions most commonly triggered by medications but increasingly recognized after exposure to iodinated contrast media (ICM). With the growing use of contrast‐enhanced imaging, clinicians are more frequently faced with diagnostic and management challenges in patients with suspected ICM‐induced reactions and with decisions regarding future contrast exposure. This systematic review aimed to synthesize published cases of ICM‐associated AGEP and ALEP, with a particular focus on clinical recognition, diagnostic evaluation in routine practice, acute management, and implications for future imaging. The review was registered in PROSPERO (CRD420251140990). Searches of PubMed/MEDLINE, Web of Science, and the Serbian Citation Index (SCIndeks) were conducted without language or date restrictions through September 9, 2025, supplemented by backward and forward citation searching. Thirty‐one publications reporting 53 patients were included. Patient age ranged from 4 to 93 years (median 56 years), and most were female (64.1%). AGEP accounted for 96.2% of cases, while ALEP was rare (3.8%). AGEP was associated with iomeprol, iodixanol, iohexol, iopromide, ioversol, iopamidol, and iobitridol. ALEP was linked to iomeprol and ioversol. Onset was typically rapid, with a median of 1 day after ICM exposure. Recurrent reactions occurred in 18.9% of patients, often with shorter latency upon re‐exposure. Reported management most frequently involved topical corticosteroids, systemic corticosteroids, and antihistamines. Nearly all patients (98.1%) recovered. Clinicians should recognize ICM as potential triggers of AGEP and ALEP and pursue appropriate diagnostic evaluation and allergological assessment to guide safe future imaging.image

News (Medical) associated with Iopromide

08 Jul 2026

·www.fiercepharma.com

Foreign drugmaker caught faking doctors’ petition to evade China’s price cut scheme

Amid an ongoing expansion of China’s volume-based procurement (VBP) scheme to lower drug costs, the Chinese government has singled out a fraud case involving a foreign originator drug in a warning to the industry. In an attempt to influence whether a drug gets selected for price bidding, a foreign drug innovator faked doctors’ signatures in a petition, China’s National Healthcare Security Administration (NHSA) said in a post (Chinese) on Tuesday. Among the 78 signatures from 31 hospitals, over 80% were found to be doctored. Some signatures were forged by sales representatives, some used misappropriated images from other sources, and some pointed to individuals that do not exist, according to the agency. As for the few signatures that the experts themselves indeed wrote, the doctors were mostly tricked into signing the document under the guise of survey questionnaires or post-sales follow-up, the agency said. The drug has since been included in the latest VBP batch of 65 drug varieties, which together represent a total market value of nearly 60 billion Chinese yuan ($8.8 billion), according to the NHSA. The VBP, now in its 12th round, is a government-led drug-buying program targeting off-patent medicines. Under the program, generics and the originators offer price cuts to secure procurement contracts with hospitals. The government unveiled the latest list on June 23 and is now in the bidding process. In a statement to local news outlet The Paper , Novartis confirmed it was not the unnamed drugmaker flagged in the NHSA alert. The Swiss pharma’s blockbuster heart failure treatment Entresto (sacubitril/valsartan) is one of the biggest products in this VBP round. According to local reports, Entresto and its generics generated more than 6 billion yuan of end-market sales ($880 million) at public hospitals in China last year, with the Novartis originator accounting for more than 90%. The VBP program now threatens to split up that huge market by rewarding significant shares to companies that offer lower prices. In what’s slated to be an über-competitive bidding process, more than 30 Entresto generics competitors are vying for a place under VBP, according to local drug intelligence database DXY Insight. As part of the largest patent expiry in Novartis’ history, Entresto lost its U.S. market exclusivity last year and has seen major sales declines since. Some uncertainties remain for VBP’s potential impact on Entresto. The Novartis drug is among eight products that carry an asterisk, which indicates ongoing patent disputes. A few days before the revelation of the latest VBP list last month, China’s National Intellectual Property Administration doled out a five-year patent-term extension to Entresto to make up for time lost during its drug regulatory review process, effectively pushing back the expiration of its core patent to November 2031. In a new rule introduced into VBP this time, generic rivals to those asterisked drugs must submit a declaration of non-infringement or be removed from procurement platforms. Takeda’s angiotensin II receptor blocker Edarbi (azilsartan medoxomil) and acid blocker Takecab (vonoprazan fumarate), Eli Lilly’s JAK inhibitor Olumiant, Daiichi Sankyo’s factor Xa inhibitor edoxaban and AstraZeneca’s Xigduo XR (dapagliflozin and metformin extended release) are also included in VBP despite ongoing patent disagreements. Takeda, Bayer and Eisai have also denied they were the company in the NHSA’s announcement, according to The Paper. Bayer’s drospirenone/ethinyl estradiol oral contraceptive, known commercially as Yaz or Yasmin, and its imaging contrast agent Ultravist (iopromide) are included for VBP bidding against generics. Eisai has anti-vertigo medication Merislon (betahistine) and anti-seizure med Fycompa (perampanel) on the list. In addition to the companies above, the 65-item roster includes brand-name products from almost all major pharmas, including Astellas, Fresenius Kabi, GSK, Johnson & Johnson, Pfizer, Merck & Co., Merck KGaA, Otsuka, Sanofi and Servier. Among the smaller firms involved are Cheplapharm, Dr. Falk Pharma and Grünenthal from Germany; Japan’s Maruishi Pharmaceutical, Sumitomo Pharma, LTL Pharma and Minophagen Pharmaceutical; as well as the Wellcome Foundation and Tillotts Pharma in Switzerland.

01 Dec 2025

·www.businesswire.com

Bayer’s MEDRAD ® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

Centargo compatible with Ultravist ® (iopromide), Isovue ® (iopamidol), Optiray ® (ioversol), Omnipaque™ (iohexol) and now, Visipaque™ (iodixanol) Follows recent FDA clearance to expand the use of compatible contrast agent presentations, adding single-dose vials in addition to Imaging Bulk Package presentations Radiology suites now have the ability to further manage contrast consumption and waste, while providing greater flexibility for those transitioning to bulk contrast use WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol) and Omnipaque™ (iohexol). Additionally, Bayer announced the addition of Visipaque™ (iodixanol) in single-dose vials as Centargo’s fifth compatible contrast agent. This expansion now offers customers in high-throughput imaging suites a wider range of compatible contrast agents and presentations from Centargo. “We know our customers operating high-volume suites, who serve dozens of patients daily, require flexible and cost-effective solutions to meet their unique needs,” said Jill Carbone, Vice President and Head of Radiology North America Product & Pipeline, Bayer. “The expanded presentations will further support healthcare providers by helping to improve efficiency in end-of-day procedures, providing greater flexibility for those still transitioning to bulk contrast use, and supporting their broad imaging needs with an option to use any of the five leading contrast agents.” The MEDRAD® Centargo CT Injection System helps reduce process and administrative burdens for healthcare providers, enabling them to focus more on patient care, particularly in high throughput settings. By integrating with Bayer’s portfolio of imaging and Cortenic™ Connectivity workflow solutions, healthcare providers can optimize contrast-usage and enable connectivity to the scanner, hospital radiology information systems and Bayer services. For more information about MEDRAD® Centargo, powered by Cortenic™ Connectivity, visit: www.Centargo.com. Full Prescribing Information for Ultravist is available at this link: https://labeling.bayerhealthcare.com/html/products/pi/Ultravist_PI.pdf About Radiology at Bayer Building on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. In 2024, Bayer’s radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including the integration of AI. About Bayer Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. For more information, go to www.bayer.com. Find more information at https://pharma.bayer.com/ Follow us on Facebook: http://www.facebook.com/bayer Follow us on X: @BayerPharma Forward-Looking Statements This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.

01 Dec 2025

·www.bayer.com

Bayer’s MEDRAD® Centargo Multi-Patient CT Injection System Now With A Wider Range of Compatible CT Contrast Agents and Presentations

WHIPPANY, N.J., December 1, 2025 – Bayer today announced that its MEDRAD® Centargo multi-patient CT injector has secured 510(k) clearance from the U.S. Food and Drug Administration (FDA) to expand the use of compatible contrast agent presentations to include single-dose vials in addition to the previously cleared Imaging Bulk Package (IBP) presentations for Ultravist® (iopromide), Isovue® (iopamidol), Optiray® (ioversol) and Omnipaque™ (iohexol). Additionally, Bayer announced the addition of Visipaque™ (iodixanol) in single-dose vials as Centargo’s fifth compatible contrast agent. This expansion now offers customers in high-throughput imaging suites a wider range of compatible contrast agents and presentations from Centargo. The MEDRAD® Centargo CT Injection System helps reduce process and administrative burdens for healthcare providers, enabling them to focus more on patient care, particularly in high throughput settings. By integrating with Bayer’s portfolio of imaging and Cortenic™ Connectivity workflow solutions, healthcare providers can optimize contrast-usage and enable connectivity to the scanner, hospital radiology information systems and Bayer services. For more information about MEDRAD® Centargo, powered by Cortenic™ Connectivity, visit: www.Centargo.com. Full Prescribing Information for Ultravist is available at this link: https://labeling.bayerhealthcare.com/html/products/pi/Ultravist_PI.pdf About Radiology at BayerBuilding on a century of expertise, Bayer is committed to innovative products and high-quality services in diagnostic imaging to enhance patient care. Its leading radiology portfolio features contrast agents and devices for precise administration across modalities including computed tomography (CT), X-ray and magnetic resonance imaging (MRI), and positron emission tomography (PET). Bayer’s comprehensive offerings also include informatics solutions and a medical imaging platform with digital and artificial intelligence (AI) powered applications. In 2024, Bayer’s radiology products generated €2.1 billion in sales. Bayer continues to advance research and innovation in medical imaging, including the integration of AI. About BayerBayer is a global enterprise with core competencies in the life science fields of health care and nutrition. In line with its mission, “Health for all, Hunger for none,” the company’s products and services are designed to help people and the planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to driving sustainable development and generating a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2024, the Group employed around 93,000 people and had sales of 46.6 billion euros. R&D expenses amounted to 6.2 billion euros. Forward-Looking StatementsThis release may contain forward-looking statements based on current assumptions and forecasts made by Bayer management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer’s public reports, which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. Media Contact: Elaine ColónBayer Media Relationselaine.colon@bayer.com +1-732-236-1587

Financial Statement

100 Deals associated with Iopromide

External Link

KEGG	Wiki	ATC	Drug Bank
D01893	Iopromide	V08AB05	DB09156

R&D Status

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Breast Diseases	United States	Bayer Healthcare LLC	25 May 2023
Breast Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	25 May 2023
Aortic Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Aortic Diseases	United States	Bayer Healthcare LLC	10 May 1995
Cardiovascular Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Cardiovascular Diseases	United States	Bayer Healthcare LLC	10 May 1995
Cerebrovascular Disorders	United States	Bayer Healthcare LLC	10 May 1995
Cerebrovascular Disorders	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Coronary Disease	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Coronary Disease	United States	Bayer Healthcare LLC	10 May 1995
Peripheral Arterial Disease	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Peripheral Arterial Disease	United States	Bayer Healthcare LLC	10 May 1995
Urethral Diseases	United States	Bayer HealthCare Pharmaceuticals, Inc.	10 May 1995
Urethral Diseases	United States	Bayer Healthcare LLC	10 May 1995
Contrast agents	Australia	Bayer Australia Ltd.	12 Sep 1991

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT04605471 (Pubmed \| Invest Radiol)	Not Applicable	-	132,850	Iopromide (Children (<18 years))	srcxkaaglx(wwdqmuncyv) = dpqhqnymgk tczxcjyuox (vhbgbukqby )	-	01 Dec 2021
				Iopromide (Elderly (≥65 years))	srcxkaaglx(wwdqmuncyv) = ahheyrgfxm tczxcjyuox (vhbgbukqby )
NCT00926562 (DIRECT, Pubmed \| EuroIntervention)	Phase 4	-	562	iopromide	mujthqexgt(tfwcooucyc) = vnnurkpafz zrhfxaggkr (bzjkccfnxk ) View more	-	22 Nov 2012
				iodixanol	mujthqexgt(tfwcooucyc) = omlkndnrky zrhfxaggkr (bzjkccfnxk ) View more
NCT00244140 (CTgov)	Phase 3	Diagnostic agents	435	Iopromide (Iopromide 370 mg I/mL)	fdntyoafqm = ygiqmkfjla vefvspvtlm (gloiarqhbj, qjfxuikmuc - wkvwugsxof) View more	-	20 Jul 2009
				Iopromide (Iopromide 300 mg I/mL)	fdntyoafqm = fywuvygriy vefvspvtlm (gloiarqhbj, zveysvonre - nirrqahexd) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis